Axonics, Inc. (AXNX) NASDAQ

70.98

+(+%)

Updated at November 14, 2024 04:00PM

Currency In USD

Axonics, Inc.

Address

26 Technology Drive

Irvine, CA 92618

United States of America

Phone

949 396 6322

Sector

Healthcare

Industry

Medical - Devices

Employees

797

First IPO Date

October 31, 2018

Key Executives

NameTitlePayYear Born
Mr. Raymond W. CohenChief Executive Officer & Director1.75M1959
Dr. Karen L. Noblett M.A.S., M.D.Chief Medical Officer651,4001963
Mr. Rinda K. SamaChief Operating Officer888,2001979
Dr. John Woock Ph.D.Executive Vice President, Chief Marketing & Strategy Officer888,2001983
Mr. Alfred J. Ford Jr.Chief Commercial Officer909,5201971
Ms. Kari KeeseChief Financial Officer1.64M1985
Mr. Michael V. Williamson Esq., J.D.Senior Vice President, General & IP Counsel01972
Mr. Aaron PettitGeneral Counsel & Chief Compliance Officer0N/A
Mr. Guangqiang Jiang Ph.D.Chief Technology Officer01974
Mr. Neil BhalodkarVice President of Investor Relations0N/A

Description

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.